Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240226 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01240226 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 22 participants.
The verdict
NCT01240226, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This will be a single-center, open-label, randomized, 2-part study to determine the relative bioavailability of GDC-0941 capsule and market-image tablet formulations and the effect of ketoconazole on the pharmacokinetics of the GDC-0941 market-image tablet formulation.
Interventions
- DRUG ketoconazole
- DRUG GDC-0941
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240226
The ClinicalTrials.gov registry entry for NCT01240226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ketoconazole is the first listed.
NCT01240226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240226 about?
NCT01240226 is a clinical study titled "A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet". This will be a single-center, open-label, randomized, 2-part study to determine the relative bioavailability of GDC-0941 capsule and market-image tablet formulations and the effect of ketoconazole on the pharmacokinetics of the GDC-0941 market-image tablet formulation.
What is the current status of trial NCT01240226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01240226?
The interventions under investigation include: ketoconazole (DRUG), GDC-0941 (DRUG).
Who is sponsoring clinical trial NCT01240226?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.